Patent · US Active

Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1

US10451610B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Mien-Chie Hung · Houston, US
Yi Du · Tangxia, CN

Key dates

Filing date	Sep 29, 2015
Grant date	Oct 22, 2019
Priority date	—
Expiry date	Jun 13, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2500/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods for identifying and treating cancers that are resistant to PARP inhibition. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. In some aspects. PARP inhibitor cancers are treated with a PARP inhibitor therapy in combination with a c-Met inhibitor therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.